New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
The transaction is expected to close in Q2 FY 2026
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
Globally, BRUKINSA is approved in more than 70 countries
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Subscribe To Our Newsletter & Stay Updated
